Video

Dr. Kumar on Treatment Considerations with BTK Inhibitors in MCL

Author(s):

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma (MCL) who progress on BTK inhibitors.

    BTK inhibitors are standard second-line treatment for patients with relapsed/refractory MCL who progress after initial chemoimmunotherapy, Kumar says. There are 3 FDA-approved BTK inhibitors including ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), and some clinicians may favor the use of acalabrutinib or zanubrutinib due to the toxicity profiles of the 3 agents, Kumar adds.

    Since patients with MCL are typically older and have multiple comorbidities, using acalabrutinib or zanubrutinib could reduce the risk of cardiovascular adverse effects, Kumar concludes.

    Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.